Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Eureka Therapeutics

- PMLiVE

Bristol Myers Squibb’s New Drug Application for mezigdomide accepted by FDA

Mezigdomide improves progression-free survival in patients with relapsed or refractory multiple myeloma

- PMLiVE

Sanofi announces phase 3 study data for infantile-onset Pompe disease

Pompe disease is a rare, progressive neuromuscular disease, with infantile onset being the most aggressive form

- PMLiVE

Sanofi’s Cenrifki approved in Europe for secondary progressive MS without relapses

SPMS is a debilitating stage of MS where patients experience increasing levels of disability

- PMLiVE

Sanofi appoints Paulo Fontoura as Global Head of R&D

Fontoura previously held senior leadership roles at Xaira Therapeutics and Roche

- PMLiVE

Sanofi’s Sarclisa approved by MHRA as UK’s first anti-cancer treatment given via on-body injector

It is the first anticancer treatment in the UK and globally to be administered this way and a first in multiple myeloma

- PMLiVE

Legend Biotech appoints new group of scientific advisors

The company is focused on CAR-T cell therapy to treat multiple myeloma

- PMLiVE

Sanofi’s Tzield gets expanded FDA approval for early-stage type 1 diabetes

The treatment can be used to delay the onset of clinical type 1 diabetes

- PMLiVE

Bristol Myers Squibb evolves and expands multiple myeloma programme

Created in 2016, the Standing in the Gaap programme aims to advance more equitable care

- PMLiVE

Gilead to acquire Arcellx in deal worth $7.8bn

The US FDA has accepted a licence application for drug for relapsed/refractory multiple myeloma

- PMLiVE

Sanofi announces positive results for venglustat in type 3 Gaucher disease

There are currently no approved treatments for the neurological symptoms of this disease

- PMLiVE

Sanofi’s Rezurock receives positive CHMP opinion for chronic graft-versus-host disease

Up to 50% of allogeneic haematopoietic stem cell transplant patients develop chronic GVHD

- PMLiVE

Johnson & Johnson’s Darzalex Faspro regimen receives FDA approval for multiple myeloma

Multiple myeloma has an average five-year survival rate of 59.8% and is currently incurable

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links